Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493596 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
A Phase 1 study, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01493596 is a Phase 1 study that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT01493596, a Phase 1 study, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Primary Objective: • To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: • To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral doses
Interventions
- DRUG Placebo
- DRUG CPP-115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493596
The ClinicalTrials.gov registry entry for NCT01493596 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01493596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493596 about?
NCT01493596 is a clinical study titled "A Safety, Tolerability and Pharmacokinetic Study of CPP-115". Primary Objective: • To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: • To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral doses
What is the current status of trial NCT01493596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2011-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01493596?
The interventions under investigation include: Placebo (DRUG), CPP-115 (DRUG).
Who is sponsoring clinical trial NCT01493596?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.